Key facts
- It has raised $225.0M across 2 recorded rounds; the latest was Later Stage VC (Series F) ($105.0M) in Jul 2023.
- 5 institutional filers report fund marks on CG Oncology across 44 filings.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for CG Oncology
Create free account
No card required
Funding rounds
2 roundsJul 2023Later Stage VC (Series F)$105.0M▮
Oct 2022Later Stage VC (Series E)$120.0M▮
About CG Oncology
- Industry
- Drug Discovery
PA Mark — not yet priced
CG Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in CG Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
5 filers · latest Jun 20265 SEC-registered funds reported 44 fair-value marks on CG Oncology between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.